Previous 10 | Next 10 |
Calithera Biosciences Inc. (NASDAQ:CALA) traded at a new 52-week low today of $2.08. So far today approximately 1.8 million shares have been exchanged, as compared to an average 30-day volume of 965,000 shares. In the past 52 weeks, Calithera Biosciences Inc. share prices are bracketed b...
Image source: The Motley Fool. Calithera Biosciences Inc (NASDAQ: CALA) Q4 2020 Earnings Call Mar 16, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences Inc (CALA) Q4 2020 Earnings Call Transcript...
Calithera Biosciences, Inc. (CALA) Q4 2020 Earnings Conference Call March 16, 2021 05:00 PM ET Company Participants Jennifer McNealey - VP, Investor Relations Susan Molineaux - Founder, President and CEO Keith Orford - Chief Medical Officer Stephanie Wong - Chief Financial Officer Conference ...
Calithera Biosciences (CALA): Q4 GAAP EPS of -$0.32 in-line.As of December 31, 2020, cash, cash equivalents and investments totaled $115.2 million.Shares +2.45%.Press Release For further details see: Calithera Biosciences EPS in-line
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and dev...
SOUTH SAN FRANCISCO, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today ann...
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today ann...
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...
Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%,&...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...